MedTrace Logo

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 349

Last updated 2016-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the addition of bupropion (Zyban) to cognitive behavioral therapy (CBT) will enhance longer-term tobacco abstinence in women.

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Bupropion

smoking cessation medication aid

DRUG

Placebo

A matched placebo pill

BEHAVIORAL

weight concerns intervention

cognitive behavioral treatment to address weight concners

BEHAVIORAL

smoking cessation intervention

Cognitive behavioral intervention for smoking cessation

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Marsha Marcus, Ph.D. · Western Psychiatric Institute & Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2009-12-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006170 on ClinicalTrials.gov